NexGel Completes Acquisition of Biomaterials from Celularity
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 21 2026
0mins
Should l Buy NXGL?
NexGel (NXGL) announced the closing of its previously announced license and acquisition of a portfolio of commercial-stage regenerative biomaterials products from Celularity (CELU), a regenerative and cellular medicine company. The Company has also launched BioNX Surgical, a new division of NEXGEL. The closing of this transaction will be financed under new terms and led by a $5.5 million strategic investment from Sequence LifeScience, a leader in regenerative medicine manufacturing. The transaction was financed through a convertible note with $0.60 conversion price and 50% warrant coverage with a strike price of $0.80.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NXGL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NXGL
About NXGL
NexGel, Inc. is a provider of healthcare, beauty, and over-the-counter products, including high-water-content hydrogels. It is engaged in manufacturing high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. It specializes in custom gels by capitalizing on proprietary manufacturing technologies. The Company operates through two segments: NexGel and CGN. Its Nexgel segment comprises the manufacturing of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, which is based in Langhorne, Pennsylvania. Its CGN segment comprises is comprised of the CGN JV used for the Company’s converting and packaging business, which is based in Granbury, Texas. Its brands include Silverseal, Hexagels, Turfguard, Kenkoderm, and Silly George. It also holds a portfolio of regenerative biomaterials which include Biovance, Biovance 3L, Natalin, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
NEXGEL Appoints New CFO to Integrate Acquisition and Accelerate Growth
- Executive Appointment: NEXGEL has appointed Ian Blackman as Chief Financial Officer, leveraging his over 30 years of experience in luxury and consumer sectors to drive the integration of the Celularity acquisition, which is expected to enhance the company's financial foundation and operational efficiency.
- Acquisition Integration Strategy: Blackman's appointment coincides with NEXGEL's final agreement with Celularity, anticipated to strengthen the company's market competitiveness and drive long-term shareholder value through the integration of regenerative medicine assets.
- Performance Enhancement: During his tenure at McIntosh Group, Blackman successfully grew revenue by over 90% and EBITDA by over 335%, and his extensive financial management experience will provide robust support for NEXGEL's future growth.
- Market Opportunities: NEXGEL's hydrogel technology platform and expanding commercial footprint present significant growth opportunities for stakeholders, and Blackman's addition will help optimize financial reporting processes and enhance the company's overall financial performance.
See More
NEXGEL NAMES IAN BLACKMAN AS CFO
New Appointment: A new Chief Financial Officer has been appointed at NEXGEL, a company focused on innovative gel technologies.
Leadership Impact: The appointment is expected to enhance the company's financial strategies and overall growth trajectory.
Company Background: NEXGEL specializes in developing advanced gel products for various applications, including healthcare and consumer markets.
Future Prospects: The new CFO's experience is anticipated to drive financial performance and support the company's expansion plans.
See More
NEXGEL's Acquisition of Celularity's Segment to Drive Profitability
- Transaction Closure: NEXGEL has successfully acquired Celularity's degenerative wound segment, expected to boost annual revenue to approximately $35 million, marking a transformation into a more scalable and diversified medical technology company, enhancing market competitiveness.
- New Division Launch: The company has established the BioNX Surgical division, focusing on advanced biomaterials for tendon repair, soft tissue reconstruction, and wound care, which is anticipated to drive commercial growth in new product lines.
- Optimized Financing Structure: The transaction secured a $5.5 million investment through convertible notes with a conversion price of $0.60 and 50% warrant coverage, expected to enhance the company's financial stability and operational capabilities.
- Positive Profit Outlook: Management anticipates that the acquisition will lead to immediate profitability, with EBITDA expected to be positive post-integration, reflecting strong market demand and growth potential in the new product lines.
See More
NEXGEL Reports Disappointing Earnings with Revenue Miss
- Disappointing Earnings: NEXGEL's FY GAAP EPS of -$0.38 missed expectations by $0.32, indicating a significant shortfall in profitability that could negatively impact investor confidence.
- Revenue Growth Challenges: Although NEXGEL reported a 31.4% year-over-year revenue increase to $11.42 million, it fell short of market expectations by $5.46 million, highlighting competitive challenges in the market.
- Market Reaction Analysis: Given the disappointing earnings report, NEXGEL's stock price may face downward pressure, prompting investors to closely monitor subsequent market dynamics and potential strategic adjustments by the company.
- Industry Comparison: Compared to top-rated companies like Delta Air Lines, NEXGEL's performance appears particularly weak, especially in terms of profitability and market share, which could affect its future financing and expansion plans.
See More
NEXGEL Moves Up Shareholder Update Call to April 21, 2026
- Meeting Reschedule: NEXGEL has moved its shareholder update conference call from April 23 to April 21, 2026, at 4:30 PM ET, aiming to communicate the latest company developments to investors more promptly.
- Call Participation Details: Investors can join the call by dialing the U.S. toll-free number 1-800-267-6316 or the international number 1-203-518-9783, ensuring global accessibility for all stakeholders to receive company updates.
- Company Overview: NEXGEL is a leading provider of healthcare, beauty, and OTC products, specializing in ultra-gentle, high-water-content hydrogel products, with over two decades of experience in development and manufacturing, featuring brands like SilverSeal® and Hexagels®.
- Strategic Partnerships: NEXGEL has established strategic contract manufacturing relationships with leading consumer healthcare companies, which not only enhances its market competitiveness but also lays the groundwork for future product innovation and market expansion.
See More
NexGel Inc Reports Significant Revenue Growth in Earnings Call
- Significant Revenue Growth: NexGel Inc (NASDAQ:NXGL) reported a substantial increase in revenue compared to the previous quarter, indicating strong sales performance that is expected to drive future financial results.
- Successful Product Launch: The company successfully launched a new product line that has been well-received in the market, further contributing to revenue growth and demonstrating the company's proactive approach to innovation.
- Expanded Distribution Network: NexGel Inc has expanded its distribution network, enhancing market reach and customer base, which lays a solid foundation for future market expansion.
- Maintained Financial Stability: The company has maintained a strong balance sheet with a healthy cash reserve, and despite facing challenges such as increased operational costs and declining international sales, management remains confident in achieving future growth targets.
See More
NEXGEL Appoints New CFO to Integrate Acquisition and Accelerate Growth
- Executive Appointment: NEXGEL has appointed Ian Blackman as Chief Financial Officer, leveraging his over 30 years of experience in luxury and consumer sectors to drive the integration of the Celularity acquisition, which is expected to enhance the company's financial foundation and operational efficiency.
- Acquisition Integration Strategy: Blackman's appointment coincides with NEXGEL's final agreement with Celularity, anticipated to strengthen the company's market competitiveness and drive long-term shareholder value through the integration of regenerative medicine assets.
- Performance Enhancement: During his tenure at McIntosh Group, Blackman successfully grew revenue by over 90% and EBITDA by over 335%, and his extensive financial management experience will provide robust support for NEXGEL's future growth.
- Market Opportunities: NEXGEL's hydrogel technology platform and expanding commercial footprint present significant growth opportunities for stakeholders, and Blackman's addition will help optimize financial reporting processes and enhance the company's overall financial performance.
See More
NEXGEL NAMES IAN BLACKMAN AS CFO
New Appointment: A new Chief Financial Officer has been appointed at NEXGEL, a company focused on innovative gel technologies.
Leadership Impact: The appointment is expected to enhance the company's financial strategies and overall growth trajectory.
Company Background: NEXGEL specializes in developing advanced gel products for various applications, including healthcare and consumer markets.
Future Prospects: The new CFO's experience is anticipated to drive financial performance and support the company's expansion plans.
See More
NEXGEL's Acquisition of Celularity's Segment to Drive Profitability
- Transaction Closure: NEXGEL has successfully acquired Celularity's degenerative wound segment, expected to boost annual revenue to approximately $35 million, marking a transformation into a more scalable and diversified medical technology company, enhancing market competitiveness.
- New Division Launch: The company has established the BioNX Surgical division, focusing on advanced biomaterials for tendon repair, soft tissue reconstruction, and wound care, which is anticipated to drive commercial growth in new product lines.
- Optimized Financing Structure: The transaction secured a $5.5 million investment through convertible notes with a conversion price of $0.60 and 50% warrant coverage, expected to enhance the company's financial stability and operational capabilities.
- Positive Profit Outlook: Management anticipates that the acquisition will lead to immediate profitability, with EBITDA expected to be positive post-integration, reflecting strong market demand and growth potential in the new product lines.
See More
NEXGEL Reports Disappointing Earnings with Revenue Miss
- Disappointing Earnings: NEXGEL's FY GAAP EPS of -$0.38 missed expectations by $0.32, indicating a significant shortfall in profitability that could negatively impact investor confidence.
- Revenue Growth Challenges: Although NEXGEL reported a 31.4% year-over-year revenue increase to $11.42 million, it fell short of market expectations by $5.46 million, highlighting competitive challenges in the market.
- Market Reaction Analysis: Given the disappointing earnings report, NEXGEL's stock price may face downward pressure, prompting investors to closely monitor subsequent market dynamics and potential strategic adjustments by the company.
- Industry Comparison: Compared to top-rated companies like Delta Air Lines, NEXGEL's performance appears particularly weak, especially in terms of profitability and market share, which could affect its future financing and expansion plans.
See More
NEXGEL Moves Up Shareholder Update Call to April 21, 2026
- Meeting Reschedule: NEXGEL has moved its shareholder update conference call from April 23 to April 21, 2026, at 4:30 PM ET, aiming to communicate the latest company developments to investors more promptly.
- Call Participation Details: Investors can join the call by dialing the U.S. toll-free number 1-800-267-6316 or the international number 1-203-518-9783, ensuring global accessibility for all stakeholders to receive company updates.
- Company Overview: NEXGEL is a leading provider of healthcare, beauty, and OTC products, specializing in ultra-gentle, high-water-content hydrogel products, with over two decades of experience in development and manufacturing, featuring brands like SilverSeal® and Hexagels®.
- Strategic Partnerships: NEXGEL has established strategic contract manufacturing relationships with leading consumer healthcare companies, which not only enhances its market competitiveness but also lays the groundwork for future product innovation and market expansion.
See More
NexGel Inc Reports Significant Revenue Growth in Earnings Call
- Significant Revenue Growth: NexGel Inc (NASDAQ:NXGL) reported a substantial increase in revenue compared to the previous quarter, indicating strong sales performance that is expected to drive future financial results.
- Successful Product Launch: The company successfully launched a new product line that has been well-received in the market, further contributing to revenue growth and demonstrating the company's proactive approach to innovation.
- Expanded Distribution Network: NexGel Inc has expanded its distribution network, enhancing market reach and customer base, which lays a solid foundation for future market expansion.
- Maintained Financial Stability: The company has maintained a strong balance sheet with a healthy cash reserve, and despite facing challenges such as increased operational costs and declining international sales, management remains confident in achieving future growth targets.
See More
